Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $84.15 | Total: $420.75 |
| 1 | 10 | $71.28 | Total: $712.80 |
| 1 | 25 | $60.39 | Total: $1,509.75 |
| 1 | 50 | $51.48 | Total: $2,574.00 |
| 1 | 100 | $44.55 | Total: $4,455.00 |
Overview
WJ-39 is an orally active aldose reductase (AR) inhibitor that ameliorates renal lesions in diabetic nephropathy through activation of Nrf2 signaling, and may be used to ameliorate renal insufficiency and fibrosis.WJ-39 inhibits oxidative stress and inhibits the activation of the inflammatory vesicle of the oligomerization structural domain-like receptor family, pyrin structural domain 3 (NLRP3).
Chemical Properties
| Molecular Formula | C19H14Cl2KNO4 |
| Molecular Weight | 430.32 |
| CAS Numbers | 3009908-95-3 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C(CN1C=C(CC2=C(Cl)C(Cl)=CC=C2)C(C3=CC(OC)=CC=C31)=O)[O-].[K+] |
Storage and Handling
0C Short Term, -20C Long Term
References
Yang L, et al. An aldose reductase inhibitor, WJ-39, ameliorates renal tubular injury in diabetic nephropathy by activating PINK1Parkin signaling. Eur J Pharmacol. 2024 Mar 15;967 176376.